WA-ITRON
14.2.2024 14:46:26 CET | Business Wire | Press release
Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, today announced a new brand identity reflecting the company’s evolution and a new era of delivering enhanced intelligence to create a more resourceful world. The new brand identity reflects Itron’s commitment to creating new efficiencies, connecting communities, encouraging sustainability and increasing resourcefulness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214395189/en/
“Itron stands at the forefront of a rapidly changing world where the challenges of energy and water scarcity, escalating demand and enabling the energy transition are more pressing than ever,” said Tom Deitrich, Itron’s president and CEO. “Our new brand identity honors our history and reflects the company we have become while demonstrating our industry leadership and dedication to understanding and solving our customers' evolving needs.”
As a proven leader of the Industrial Internet of Things (IIoT) with one of the largest connected platforms and installed bases in the energy, water and smart city sectors, Itron is providing more intelligence at the grid edge and driving a smoother transition to cleaner energy and water delivery while transforming the way grid operators address critical challenges. Itron invents new ways for cities and utilities to work together so they can cost-effectively leverage the same intelligent grid edge infrastructure to deliver multiple services and applications on a reliable, resilient network capable of serving all stakeholders.
This new brand identity serves as a strategic move for Itron as the company expands its offerings, signaling to the market the company’s evolution and growth in several key focus areas:
- Electricity: Enabling improved visibility and control at the grid edge. Boosting utility and city customers’ energy efficiency and cost savings and enabling the transition to lower-carbon energy, EVs and a more robust, resilient and reliable grid.
- Water: Safeguarding the water supply, finding leaks, reducing waste and improving safety.
- Smart Cities: Connecting, protecting and unlocking endless possibilities for more sustainable, thriving communities.
- Gas: Ensuring safety and integrity in the natural gas delivery system while unlocking more insights from that same system than ever before.
- Sustainability: Leaving a legacy of responsible energy and water management and reducing both Itron’s and its customers’ carbon footprint.
As part of the refreshed brand identity, Itron is introducing a more modern logo that showcases a leaner font, a more upright design, more modern lines and richer, deeper colors. The ray or beam of light shining out from the ‘O’ symbolizes Itron’s leadership and ability to light the way forward for the industry.
“At Itron, we are a catalyst for positive change, delivering intelligent, secure and reliable solutions that power homes, ensure the delivery of clean water and contribute to well-lit and safer streets, enabling a brighter, more sustainable future,” said Marina Donovan, Itron’s vice president of global marketing, ESG and public affairs. “Our new brand identity reflects and projects our edge intelligence offerings and a new era for Itron.”
For more details on Itron’s new brand identity, see the Itron Press Kit, which features brand guidelines, logo files and updated fact sheet and watch the brand history video. Also visit Itron at DISTRIBUTECH International, Feb. 27-29, 2024, in booth #2200 where the new brand will be on full display.
About Itron
Itron is a proven global leader in energy, water, smart city, IIoT and intelligent infrastructure services. For utilities, cities and society, we build innovative systems, create new efficiencies, connect communities, encourage conservation and increase resourcefulness. By safeguarding our invaluable natural resources today and tomorrow, we improve the quality of life for people around the world. Join us: www.itron.com.
Itron® is a registered trademark of Itron, Inc. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.
Additional Resources
- LinkedIn: https://www.linkedin.com/company/itroninc/
- X: https://twitter.com/ItronInc
- Newsroom: www.itron.com/company/newsroom
- Blog: https://blogs.itron.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214395189/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom